Log in

Unum Therapeutics Stock Price, News & Analysis (NASDAQ:UMRX)

$1.32
-0.09 (-6.38 %)
(As of 10/23/2019 09:01 AM ET)
Today's Range
$1.24
Now: $1.32
$1.46
50-Day Range
$1.30
MA: $1.68
$2.10
52-Week Range
$1.23
Now: $1.32
$9.27
Volume148,261 shs
Average Volume41,400 shs
Market Capitalization$40.47 million
P/E RatioN/A
Dividend YieldN/A
Beta1.26
Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL). Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:UMRX
CUSIPN/A
Phone617-945-5576

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$9.73 million
Book Value$2.01 per share

Profitability

Net Income$-34,530,000.00
Net Margins-340.49%

Miscellaneous

Employees56
Market Cap$40.47 million
Next Earnings Date11/11/2019 (Estimated)
OptionableNot Optionable

Receive UMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for UMRX and its competitors with MarketBeat's FREE daily newsletter.


Unum Therapeutics (NASDAQ:UMRX) Frequently Asked Questions

What is Unum Therapeutics' stock symbol?

Unum Therapeutics trades on the NASDAQ under the ticker symbol "UMRX."

How were Unum Therapeutics' earnings last quarter?

Unum Therapeutics Inc (NASDAQ:UMRX) issued its quarterly earnings results on Monday, August, 12th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.05. The company earned $3.14 million during the quarter, compared to analysts' expectations of $3.10 million. Unum Therapeutics had a negative return on equity of 75.60% and a negative net margin of 340.49%. View Unum Therapeutics' Earnings History.

When is Unum Therapeutics' next earnings date?

Unum Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November 11th 2019. View Earnings Estimates for Unum Therapeutics.

What price target have analysts set for UMRX?

4 brokerages have issued twelve-month price targets for Unum Therapeutics' stock. Their forecasts range from $6.00 to $18.00. On average, they expect Unum Therapeutics' stock price to reach $12.33 in the next year. This suggests a possible upside of 834.3% from the stock's current price. View Analyst Price Targets for Unum Therapeutics.

What is the consensus analysts' recommendation for Unum Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unum Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Unum Therapeutics.

What are Wall Street analysts saying about Unum Therapeutics stock?

Here are some recent quotes from research analysts about Unum Therapeutics stock:
  • 1. According to Zacks Investment Research, "Unum Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel immunotherapy products of immune system to cure cancer. The company's program consists of ACTR087 rituximab, ACTR707 RITUXIMAB, ACTR087 SEA-BCMA which are in clinical stage. Unum Therapeutics Inc. is based in Cambridge, United States. " (10/19/2019)
  • 2. HC Wainwright analysts commented, "Our price target of $18/share is based on an equally-weighted composite of: (a) $18.0/share, as a 25x multiple of taxed and diluted $7.63 discounted back to FY19 at 30% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $17.5/share (discounted cash flow analysis using a 18.0% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (8/13/2019)

Has Unum Therapeutics been receiving favorable news coverage?

Press coverage about UMRX stock has been trending negative on Wednesday, according to InfoTrie. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Unum Therapeutics earned a media sentiment score of -2.5 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Unum Therapeutics.

Who are some of Unum Therapeutics' key competitors?

What other stocks do shareholders of Unum Therapeutics own?

Who are Unum Therapeutics' key executives?

Unum Therapeutics' management team includes the folowing people:
  • Dr. Charles Wilson, CEO, Pres & Director (Age 54)
  • Mr. Michael J. Vasconcelles, Chief Medical Officer (Age 55)
  • Dr. Dario Campana, Scientific Founder & Chair of Scientific Advisory Board
  • Mr. John L. Green, VP of Fin. (Age 39)
  • Mr. Geoffrey Hodge, Chief Technical Officer & Sr. VP of Operations (Age 54)

When did Unum Therapeutics IPO?

(UMRX) raised $75 million in an initial public offering (IPO) on Thursday, March 29th 2018. The company issued 5,800,000 shares at $12.00-$14.00 per share. Morgan Stanley and Cowen served as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush Securities were co-managers.

Who are Unum Therapeutics' major shareholders?

Unum Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Wedbush Securities Inc. (0.11%). Company insiders that own Unum Therapeutics stock include Liam Ratcliffe, Seth Ettenberg and Venture Fund Ix LP Atlas. View Institutional Ownership Trends for Unum Therapeutics.

Which institutional investors are buying Unum Therapeutics stock?

UMRX stock was bought by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. Company insiders that have bought Unum Therapeutics stock in the last two years include Liam Ratcliffe and Venture Fund Ix LP Atlas. View Insider Buying and Selling for Unum Therapeutics.

How do I buy shares of Unum Therapeutics?

Shares of UMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Unum Therapeutics' stock price today?

One share of UMRX stock can currently be purchased for approximately $1.32.

How big of a company is Unum Therapeutics?

Unum Therapeutics has a market capitalization of $40.47 million and generates $9.73 million in revenue each year. The company earns $-34,530,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis. Unum Therapeutics employs 56 workers across the globe.View Additional Information About Unum Therapeutics.

What is Unum Therapeutics' official website?

The official website for Unum Therapeutics is http://www.unumrx.com/.

How can I contact Unum Therapeutics?

Unum Therapeutics' mailing address is 200 CAMBRIDGE PARK DRIVE SUITE 3100, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-945-5576 or via email at [email protected]


MarketBeat Community Rating for Unum Therapeutics (NASDAQ UMRX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  126 (Vote Outperform)
Underperform Votes:  130 (Vote Underperform)
Total Votes:  256
MarketBeat's community ratings are surveys of what our community members think about Unum Therapeutics and other stocks. Vote "Outperform" if you believe UMRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe UMRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel